Related Experiment Videos
[The effectiveness of antiplatelet therapy in ischemic cerebrovascular attacks in the chronic stage]
Insights
For patients with carotid circulation ischaemic cerebrovascular attacks, antithrombocytic drugs show significant benefits for one year. After two years, routine drug administration is not recommended; clinical evaluation is advised.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Hematology
Context:
- Investigating long-term efficacy of antithrombocytic drugs in patients post-ischaemic cerebrovascular attack (CVA).
- Focus on patients with carotid circulation involvement, a common site for CVAs.
- Utilizing comprehensive diagnostics including cerebral angiography and platelet aggregation studies.
Purpose:
- To determine the optimal duration for antithrombocytic drug therapy after an ischaemic CVA.
- To evaluate the sustained clinical benefit of these medications beyond one year.
- To establish criteria for discontinuing or continuing antithrombocytic treatment.
Summary:
- A study of 69 patients with ischaemic CVAs demonstrated significant benefits from antithrombocytic drugs up to one year post-event.
- Statistical analysis indicated no significant difference in clinical outcomes between treatment and control groups after two years.
- The study suggests routine antithrombocytic drug use may not be necessary for stabilized patients two years after their CVA.
Impact:
- Recommends personalized treatment strategies, moving away from routine long-term antithrombocytic drug administration.
- Advocates for regular clinical assessment and platelet aggregation monitoring to guide treatment decisions.
- Provides evidence-based guidance for managing patients after ischaemic cerebrovascular events, potentially reducing unnecessary medication and associated risks.
Abstract:
Sixty-nine patients, mean age 50.0 years with an ischaemic cerebrovascular attack in the carotid circulation were subjected since 1983 to a complete examination incl. cerebral angiography. Based on the case-history, clinical examination, evaluation of results of cerebral angiography, haematological examination focused on platelet aggregation and statistical evaluation, the author assessed the shortest necessary period of the use of antithrombocytic drugs. One year after the attack a significant effect of the use of these drugs was proved, after two years, however, the H0 hypothesis on the independence of the clinical condition and treatment cannot be refuted. Based on these results the author recommends that to these stabilised patients after two years from the attack drugs should not be administered as a matter of routine; the patients should be subjected to a clinical examination and examination of circulating platelet aggregates with the possibility to discontinue antithrombocytic treatment. The author discusses the method of W. U. Hoak for the evaluation of the effectiveness of antithrombocytic treatment.